<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420888</url>
  </required_header>
  <id_info>
    <org_study_id>06762004</org_study_id>
    <nct_id>NCT00420888</nct_id>
  </id_info>
  <brief_title>ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma</brief_title>
  <official_title>A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Active Biotech AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Active Biotech AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The drug ABR-217620/naptumomab estafenatox is a fusion of two proteins, one that recognizes
      tumor cells and one that triggers an attack on the tumor cells by activating some white blood
      cells belonging to the body's normal immune system. This results in an accumulation of white
      blood cells in the cancer that can fight the cancer. This study will compare the safety and
      effectiveness (assessed by tumor status and survival) of ABR-217620/naptumomab estafenatox
      when given with standard therapy IFN-alpha to IFN-alpha alone in patients with advanced renal
      cell carcinoma (RCC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to death</measure>
    <time_frame>every 12 weeks, including after a maximum of 18 months of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival time</measure>
    <time_frame>every 12 weeks for the 18-month treatment period and also every 12 weeks after the treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate</measure>
    <time_frame>every 12 weeks for the 18-month treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>every 12 weeks for the 18-month treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>every 12 weeks for the 18-month treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sum of target lesions</measure>
    <time_frame>every 12 weeks for the 18-month treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological response in patients on combined treatment of ABR-217620/naptumomab estafenatox and IFN-alpha</measure>
    <time_frame>Weeks 1, 9, 17, 25, 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>every visit through Week 25, plus Week 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical measurements</measure>
    <time_frame>Weeks 1, 9, 17, 25, 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>every visit through Week 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory safety assessments</measure>
    <time_frame>Weeks 1, 2, 3, 5, 9, 10, 13, 17, 18, 21, 25, and 73</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of ABR-217620/naptumomab estafenatox</measure>
    <time_frame>Weeks 1, 9, and 17</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">526</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Safety group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-12 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABR-217620/naptumomab estafenatox</intervention_name>
    <description>10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times</description>
    <arm_group_label>Safety group</arm_group_label>
    <arm_group_label>1</arm_group_label>
    <other_name>naptumomab estafenatox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN-alpha</intervention_name>
    <description>3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week</description>
    <arm_group_label>Safety group</arm_group_label>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Referon-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed RCC (clear cell and papillary types)

          -  Metastatic or inoperable locally advanced RCC

          -  Eligible for therapy with IFN-alpha.

          -  Measurable disease defined by at least 1 measurable lesion on CT scan (lesion diameter
             greater than or equal to 2.0 cm by a standard CT scanner or greater than or equal to
             1.0 cm by a spiral CT scanner)

          -  Favorable or moderate risk group prognosis by MSKCC (Motzer) criteria (score 0-2)

          -  Karnofsky performance status greater than or equal to 70

          -  Age greater than or equal to 18

          -  Life expectancy greater than 3 months

          -  Baseline blood counts:

               -  Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L

               -  Platelets greater than or equal to 100 x 10^9/L

               -  Haemoglobin greater than or equal to 100 g/L

          -  Baseline blood chemistry levels:

               -  Creatinine less than or equal to 1.5 x upper limit of normal (ULN)

               -  Bilirubin less than or equal to 2 x ULN

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or
                  equal to 2.5 x ULN. AST and ALT allowed less than or equal to 5 x ULN for
                  patients with liver metastases.

          -  If fertile, patient will use effective method of contraception throughout the study

          -  Willing and able to comply with the treatment and follow-up visits and examinations

          -  Capable of understanding the parameters in the protocol and able to sign a written
             consent form

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  Serious uncontrolled medical disorder or active infection ongoing or resolved within 2
             weeks before first dose of study drug and that the investigator believes would impair
             the patient's ability to receive study drug

          -  History of malignancy within 5 years or concurrent malignancy, except successfully
             treated non-melanoma skin cancer, cervical cancer in situ, ductal carcinoma in situ or
             lobular carcinoma in situ of breast may be included

          -  History and/or signs of parenchymal brain metastases

          -  Significant cardiac disease including: history (within 6 months) or current unstable
             angina pectoris, congestive heart failure (NYHA stage III-IV), myocardial infarction
             within 12 months, or uncontrolled arterial hypertension.

          -  History of stroke within 5 years and/or transient ischemic attack within 6 months.

          -  Acute illness or evidence of infection, including unexplained fever (&gt;100.5ºF or
             38.1ºC) within 2 weeks before start of treatment

          -  Treatment with biological response modifiers within 3 weeks prior to the start of
             treatment and up to the End-of-Study visit

          -  Treatment with beta-blockers, including topical therapy for glaucoma, within 5 days
             before start of treatment and during the 4-day ABR-217620/naptumomab estafenatox
             treatment

          -  Treatment with systemic corticosteroids within 2 weeks before start of treatment or
             likely need for such treatment during the study

          -  Active autoimmune disease requiring therapy or any history of systemic lupus
             erythematosus or rheumatoid arthritis

          -  Known positive serology for HIV

          -  Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the
             liver or history of chronic virus hepatitis or known virus carrying; patients who
             recovered from Hepatitis A are allowed

          -  Treatment with anticoagulants within 2 weeks before start of treatment, except when
             used to maintain the patency of a central or peripheral venous line

          -  Radiotherapy less than 4 weeks before start of treatment

          -  Major surgery or tumor embolization less than 4 weeks before start of treatment

          -  Previous exposure to murine monoclonal antibodies or known hypersensitivity to murine
             proteins

          -  Currently on renal dialysis treatment

          -  Known allergy or hypersensitivity to aminoglycosides and kanamycin

          -  Previous systemic anti-tumor therapy for RCC (including immunotherapy with IFN-alpha
             or IL-2 or any chemotherapy) except sunitinib or other oral antiangiogenic therapy

          -  Participation in any study with investigational drugs for RCC within 6 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thore Nederman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Active Biotech AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Chemotherapy, University General Hospital for Active Treatment &quot;Georgi Stranski&quot;</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Internal Department District Dispensary for Cancer Diseases with Inpatient Hospital</name>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multifile Hospital &quot;Aleksandrovska&quot;, Urology Clinic, Department of Oncourology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Clinic, University General Hospital for Active Treatment &quot;Tzaritza Yoanna&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Clinic, General Hospital for Active Treatment &quot;St. Anna&quot;</name>
      <address>
        <city>Varna</city>
        <zip>9002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Chemotherapy, Inter-district Dispensary for Cancer Diseases with Inpatient Hospital</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute - Urology Department</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dinu Uromedica</name>
      <address>
        <city>Bucharest</city>
        <zip>041345</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Prof. Dr. Th. Burghele&quot; Clinical Hospital, Urology Clinic</name>
      <address>
        <city>Bucharest</city>
        <zip>050659</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;I. Chiricuta&quot; Institute of Oncology</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E-URO Medical Center</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400016</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Provita Center SRL</name>
      <address>
        <city>Constanta</city>
        <zip>900635</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibiu Clinical Country Hospital - Urology Clinic</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncomed SRL</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Oncology Center</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Oncology Center</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Center</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan City Oncology Center</name>
      <address>
        <city>Kazan</city>
        <zip>420111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Urology</name>
      <address>
        <city>Moscow</city>
        <zip>105425</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Oncological Research Center n.a. N.N. Blokhin</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Research Center of Radiology</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Radiology Research Center</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg Regional Clinical Oncology Center</name>
      <address>
        <city>Orenburg</city>
        <zip>460021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Oncological Center</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Aleksandrovskaya Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Multi-Speciality Hospital #2</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Hospital #26</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Oncology Center</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Research Institute of Roentgenology and Radiology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Oncology n.a. Professor N.N. Petrov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Hospital #15</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol Territorial Clinical Oncology Center</name>
      <address>
        <city>Stavropol</city>
        <zip>355047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkassy Regional Oncology Center</name>
      <address>
        <city>Cherkassy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernigov Regional Oncology Center</name>
      <address>
        <city>Chernigov</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Department, Dnepropetrovsk State Medical Academy</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City General Hospital #4</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk Regional Antitumor Center</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankovsk Regional Oncology Center</name>
      <address>
        <city>Ivano-Frankovsk</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv Regional Urology and Nephrology Center</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Urology under the Academy of Medical Sciences of Ukraine, Department of Plastic and Supportive Urology</name>
      <address>
        <city>Kiev</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Urology under the Academy of Medical Sciences of Ukraine, Urology Department</name>
      <address>
        <city>Kiev</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Regional Diagnostics and Treatment Oncology Center</name>
      <address>
        <city>Lvov</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Center</name>
      <address>
        <city>Uzhorod</city>
        <zip>88014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital, Cambridge Clinical Trials Centre</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derby Hospital NHS Trust</name>
      <address>
        <city>Derby</city>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Institute of Oncology</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW6 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Wales Cancer Institute, Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Norway</country>
  </removed_countries>
  <results_reference>
    <citation>Hawkins R, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P, Karyakin O, Khasanov R, Hedlund G, Forsberg G, Nordle Ö, Eisen T. A randomized phase 2/3 study of naptumomab estafenatox plus IFN-α vs IFN-α in advanced renal cell carcinoma. ASCO Annual Meeting 2013; Abstract ID: 3073.</citation>
  </results_reference>
  <results_reference>
    <citation>Eisen T, Hedlund G, Forsberg G, Nordle Ö, Hawkins R. Baseline biomarker trend analysis of a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α vs IFN-α in advanced renal cell carcinoma. European Cancer Congress (ECCO) 2013; Abstract ID: 2710.</citation>
  </results_reference>
  <results_reference>
    <citation>Elkord E, Burt DJ, Sundstedt A, Nordle Ö, Hedlund G, Hawkins RE. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α. Oncotarget. 2015 Feb 28;6(6):4428-39.</citation>
    <PMID>25669986</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <disposition_first_submitted>June 2, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 1, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 8, 2014</disposition_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

